Proton Pump Inhibitor Therapy for Peptic Ulcer Bleeding: Cochrane Collaboration Meta-analysis of Randomized Controlled Trials

Leontiadis, Grigoris I.; Sharma, Virender K.; Howden, Colin W.
March 2007
Mayo Clinic Proceedings;Mar2007, Vol. 82 Issue 3, p286
Academic Journal
OBJECTIVE: To evaluate the efficacy of proton pump inhibitors (PPIs) in treating peptic ulcer bleeding. MATERIAL AND METHODS: We searched the MEDLINE, EMBASE, CENTRAL, Cochrane Library, and metaRegister of Controlled Trials databases and published proceedings of major meetings through November 2004 for randomized controlled trials that compared oral or intravenous PPIs with placebo or a histamine2-receptor antagonist for peptic ulcer bleeding. Pharmaceutical companies and relevant experts were contacted. Data extraction and assessment of study validity were performed independently in duplicate. Assessed outcomes were 30-day all-cause mortality, rebleeding, surgery, and repeated endoscopic treatment. Influence of study characteristics on outcomes was examined by subgroup analyses and meta-regression. RESULTS: We included 24 trials (4373 participants). Statistical heterogeneity was evident only for rebleeding. Treatment with PPIs had no significant effect on mortality (odds ratio [OR], 1.01; 95% confidence interval [Cl], 0.74-1.40; number needed to treat [NNT], incalculable) but significantly reduced rebleeding (OR, 0.49; 95% Cl, 0.37-0.65; NNT, 13) and the need for surgery (OR, 0.61; 95% Cl, 0.48-0.78; NNT, 34) and repeated endoscopic treatment (OR, 0.32; 95% Cl, 0.20-0.51; NNT, 10). Results were similar when analysis was confined to trials with adequate allocation concealment. Treatment with PPIs significantly reduced mortality in Asian trials (OR, 0.35; 95% Cl, 0.16-0.74; NNT, 34) and in patients with active bleeding or a nonbleeding visible vessel (OR, 0.53; 95% Cl, 0.31-0.91; NNT, 50). CONCLUSIONS: In ulcer bleeding, PPIs reduce rebleeding and the need for surgery and repeated endoscopic treatment. They improve mortality among patients at highest risk.


Related Articles

  • High- Versus Low-Dose Proton Pump Inhibitors After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding: A Multicentre, Randomized Study. Andriulli, Angelo; Loperfido, Silvano; Focareta, Rosaria; Leo, Pietro; Fornari, Fabio; Garripoli, Antonietta; Tonti, Paolo; Peyre, Sergio; Spadaccini, Antonio; Marmo, Riccardo; Merla, Antonio; Caroli, Alessandro; Forte, Gian Battista; Belmonte, Angelo; Aragona, Giovanni; Imperiali, Gianni; Forte, Fabrizio; Monica, Fabio; Caruso, Nazario; Perri, Francesco // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3011 

    BACKGROUND: The most effective schedule of proton pump inhibitor (PPI) administration following endoscopic hemostasis of bleeding ulcers remains uncertain. METHODS: Patients with actively bleeding ulcers and those with nonbleeding visible vessel or adherent clot were treated with epinephrine...

  • H. PYLORI ERADICATION OPTIONS FOR PEPTIC ULCER DISEASE.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, p126 

    A table is presented which lists proton-pump inhibitor drugs for treating peptic ulcers including Aciphex, Prevacid and Helidac.

  • Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Wedemeyer, Ralph-Steven; Blume, Henning // Drug Safety;Apr2014, Vol. 37 Issue 4, p201 

    Proton pump inhibitors (PPIs) are used extensively for the treatment of gastric acid-related disorders, often over the long term, which raises the potential for clinically significant drug interactions in patients receiving concomitant medications. These drug-drug interactions have been...

  • Antacids and Anticholinergic Drug. Littman, Armand; Pine, Brian H. // Annals of Internal Medicine;Apr75, Vol. 82 Issue 4, p544 

    Discusses the effectiveness of antacids and anticholinergic drugs in gastrointestinal disease treatment. Mode of action of antacids; Use of antacid in the treatment of peptic ulcer; Effect of anticholinergic drugs on acid contents of the stomach; Effectiveness of anticholinergic drugs in peptic...

  • CLINICAL EXPERIENCE WITH A NEW ANTACID PREPARATION. Plotz, Milton; Slanger, Alexander // American Journal of Gastroenterology;Jan1960, Vol. 33 Issue 1, p90 

    Although there is no question of the value of an antacid in the treatment of peptic ulcer and conditions associated with gastric hyperacidity, there is a continuous search for an ideal antacid preparation. Magnesium trisilicate has slow-acting prolonged acid-neutralizing adsorptive properties...

  • Overprescribing proton pump inhibitors. Forgacs, Ian; Loganayagam, Aathavan // BMJ: British Medical Journal (International Edition);1/5/2008, Vol. 336 Issue 7634, p2 

    The authors reflect on the overprescribing of proton pump inhibitors. They suggest that between 25% and 70% of patients taking the inhibitors have no appropriate indication for their use, that evidence for their use is lacking, and they are not cost effective. He argues that based on...

  • GORD and the acid pocket. MacFarlane, Brett // Australian Journal of Pharmacy;Aug2015, Vol. 96 Issue 1142, p86 

    The article discusses the role community pharmacies can play in providing access to effective treatment for gastro-oesophageal reflux disease (GORD). It mentions the General Practice Activity in Australia 2013-14 report, which reveals the number of Australians experiencing reflux symptoms. It...

  • RISK OF BACTERIAL INFECTION IN ELDERLY PATIENTS ON PPIS. Deasy, JoAnn // Clinical Advisor;Jan2010, Vol. 13 Issue 1, p42 

    The article focuses on the greater risks for elderly patients to obtain bacterial infection on the use of proton-pump inhibitors (PPI) in the U.S. The use of PPIs and antacids as a therapy has been viewed disadvantageous because it increase the risk of hospital-acquired pneumonia. Moreover, the...

  • Peptic ulcers respond to acid-reducer medications. Zablocki, Elaine // Managed Healthcare Executive;Dec2008, Vol. 18 Issue 12, p26 

    The article discusses the treatment for peptic ulcers. The disease is prevalent in the U.S. and the common causes include the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and infection with Helicobacter pylori (H. pylori) bacteria. The treatment for peptic ulcers includes medications...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics